Active substance
Results for the substance midostaurin
1 result
About this active substance
Midostaurin is a kinase inhibitor used for the treatment of acute myeloid leukemia with FLT3 mutation and advanced systemic mastocytosis. It works by inhibiting the activity of kinases involved in abnormal cell proliferation.
The medication is taken orally, usually twice daily, with the dose adjusted based on the patient's response and tolerability. Common side effects include nausea, vomiting, diarrhea, and neutropenia.
Midostaurin is contraindicated in patients with hypersensitivity to the active substance. Its use also requires careful monitoring of blood counts and liver function.
This medication is an important option for patients with acute myeloid leukemia and systemic mastocytosis, helping to improve their prognosis.
The medication is taken orally, usually twice daily, with the dose adjusted based on the patient's response and tolerability. Common side effects include nausea, vomiting, diarrhea, and neutropenia.
Midostaurin is contraindicated in patients with hypersensitivity to the active substance. Its use also requires careful monitoring of blood counts and liver function.
This medication is an important option for patients with acute myeloid leukemia and systemic mastocytosis, helping to improve their prognosis.